Ticker Sage

Earnings recap · JNJ

Johnson & Johnson Q3 2026 results

What Johnson & Johnson reported for Jul to Sep 2026, compared with the same quarter a year earlier, from the press release it filed with the SEC.

Source The press release Johnson & Johnson filed with the SEC on Oct 13, 2026 as Exhibit 99.2 to a Form 8-K (Item 2.02). The quarterly report (10-Q), with full financial statements and notes, hadn't been filed when this page was built. This page will say so here when it is.

The headline numbers

Johnson & Johnson reported sales of $25.4B for Q3 2026, compared with $24.0B a year earlier (+5.9%). Net earnings was $210M, compared with $5.2B (−95.9%), and diluted earnings per share were $0.09, compared with $2.12. These are GAAP figures, prepared under the standard accounting rules. How EPS is calculated.

Johnson & Johnson's quarter compared with a year earlier

Comparing Q3 2026 (Jul to Sep 2026) with Q3 2025 (Jul to Sep 2025)

Each pair of bars shows both periods. Longer bar, more money. Bars in a group share one scale.

Q3 2026Q3 2025

Revenue and profit (GAAP)

Sales
$25.4B Q3 2026
$24.0B Q3 2025
5.9% increase
Net earnings
$210M Q3 2026
$5.2B Q3 2025
95.9% decrease

Source: Exhibit 99.2 to Johnson & Johnson's 8-K filed Oct 13, 2026

Per share (GAAP)

Diluted EPS
$0.09 Q3 2026
$2.12 Q3 2025
95.8% decrease

Source: Exhibit 99.2 to Johnson & Johnson's 8-K filed Oct 13, 2026

Johnson & Johnson income statement highlights, Q3 2026 vs Q3 2025 (GAAP)
LineQ3 2026Q3 2025Change
Sales$25,399M$23,993M+5.9%
Net earnings$210M$5,152M−95.9%
Diluted EPS$0.09$2.12−95.8%

Change is worked out by Ticker Sage from the two figures shown.

What to look for in the 10-Q

The press release has the headline tables. The 10-Q adds the full statements, the notes and management's discussion, including:

How an 8-K, a 10-Q and a 10-K differ. When the 10-Q is filed, the box at the top of this page links to it.

Sources

Common questions

When did Johnson & Johnson report Q3 2026 results?

Johnson & Johnson filed its Q3 2026 press release with the SEC on Oct 13, 2026, as Exhibit 99.2 to a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

What were Johnson & Johnson's revenue and EPS for Q3 2026?

Sales was $25.4B, compared with $24.0B in Q3 2025. Diluted EPS was $0.09, compared with $2.12.

Has Johnson & Johnson filed its 10-Q for Q3 2026?

Not when this page was built. Companies file the 10-Q a few weeks after quarter end, by a deadline the SEC sets by company size. This page links to it once it is filed.

Johnson & Johnson company file → · Johnson & Johnson filings news · Learn

Disclosures

Editor holdings in JNJ
The editor holds no position in Johnson & Johnson (JNJ). As of Oct 25, 2026.
Compensation
Nobody paid for this page. No affiliate links.
Sources
Johnson & Johnson's own SEC filings, linked next to each number.
Last updated
Oct 26, 2026

A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold JNJ. It reports what the company said and doesn't compare the results with forecasts by anyone else.